Search results
Spire Wealth Management Increases Position in Novo Nordisk A/S (NYSE:NVO)
ETF DAILY NEWS· 6 hours agoSpire Wealth Management grew its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 52.5% in the 4th quarter, according to the company in ...
Novo Nordisk announces $6B investment in Ozempic, Wegovy amid shortages
ABC News· 7 days agoAn executive for Novo Nordisk, the maker of popular drugs used for weight loss including Ozempic and...
Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Choreo LLC
ETF DAILY NEWS· 5 days agoChoreo LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 6.7% during the 4th quarter, according to its most recent filing ...
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
Bankrate via AOL· 18 hours agoThis could be a game-changer compared to the weekly injections required by current market leaders,...
Novo, Catalent Deal Set to Underpin FTC Vertical Merger Scrutiny
Bloomberg Law· 3 days agoto buy a key manufacturer presents an opening for the US Federal Trade Commission to take action against vertical mergers and pharmaceutical industry consolidation. —a step that could lead to ...
Why Weight-Loss Drugs Wegovy, Zepbound Are in Short Supply
The Business of Fashion· 7 days agoShortages have left patients already on the medications searching for their next dose and stymied...
Apple, Glencore, Sony, Novo Nordisk, Shell, Goldman Sach, GSK, Qualcomm, AMD, Starbucks, Amazon –...
Proactive Investors· 5 days agoApple Inc (NASDAQ:AAPL, ETR:APC) investors welcomed the iPhone maker’s latest earnings report on Thursday, buying up the shares following Thursday’s report. Revenues came ...
How the CFOs of Eli Lilly and Novo Nordisk are coping with ‘unprecedented demand’ for weight-loss...
Fortune· 6 days agoIndianapolis-based Eli Lilly (no. 142 on the Fortune 500) is the maker of Mounjaro, classified as Type 2 diabetes drug but which has led to weight loss among patients, and Zepbound, an obesity ...
Here are the obesity drug hopefuls vying to unseat Ozempic, Zepbound
San Francisco Chronicle· 6 days agoAfter Amgen Inc.’s chief executive officer, Robert Bradway, said he was “very encouraged” by early results of an experimental...its biggest gain since 2009. The CEO’s upbeat ...
More than 100 groups spent over $20k lobbying the Kentucky legislature. Who are they?
Lexington Herald-Leader via Yahoo Finance· 4 hours ago..., LLC: $22,500.00 Inseparable Action, Inc.: $22,500.00 ECL Entertainment, LLC: $22,500.00 KY...